Eli Lilly has partnered with the National Center for Cardiovascular Diseases (NCCD) in China to promote scientific understanding and care for patients with type 2 diabetes and related disorders, including cardiovascular disease (CVD).
The collaboration will see four strategic initiatives, comprising assessment of the health economic consequences of diabetes in the country and examination of patient samples to detect new biomarkers for progression of diabetes, diabetic kidney diseases (DKD) and CVD.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
In addition, the partners will focus on developing a CVD risk calculator aimed at enhancing screening and disease management at the primary care level.
They will also create and distribute medical education for healthcare professionals involved in the treatment of diabetes-related CVD in China.
NCCD assistant director Lixin Jiang said: “As the number of people living with diabetes continues to grow rapidly throughout China, it is imperative that we address the human and economic impact of the condition.
“Diabetes often leads to complications, including cardiovascular disease. By advancing our understanding of diabetes and cardiovascular disease, we have an opportunity to significantly improve care for people in China.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataLilly and NCCD will utilise data from the patient-centred Evaluative Assessment of Cardiac Events (PEACE) Million Persons Project designed as an epidemiological screening programme in the country.
It is estimated that the project can provide access to data from more than one million people with type 2 diabetes and increased risk for CVD.
Lilly scholar Robert Heine said: “Our hope is this collaboration will produce learning and tools that will benefit people living with type 2 diabetes in China and elsewhere around the world.”
Statistics indicate growth of diabetes patients in China from more than 1% of the population in 1980 to about 11% in 2017, which also led to a rise in related complications.
